Announced details
Immune cell therapy for malignant glioma (glioblastoma)
Enhanced target antigen-specific cytotoxic activity, increased interferon-gamma production capacity, and potent antigen-specific cytotoxic activity against glioblastoma spheroids
Kagawa International Conference Hall / Sunport Hall Takamatsu (conference venue); Drug Discovery Research Department, Kobe Research Institute, HEALIOS K.K. (presenter's affiliation)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
30th Annual Meeting of the Japanese Association for Cancer Immunology (https://med-gakkai.jp/jaci2026/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Dual CAR-eNK cells (iPS cell-derived genetically modified NK cells expressing chimeric antigen receptors targeting EGFR and PD-L1), eNK® cells |
| Launch date | 23 July 2026 (scheduled; poster presentation at the conference) |
| Applicable area | Immune cell therapy for malignant glioma (glioblastoma) |
| Location | Kagawa International Conference Hall / Sunport Hall Takamatsu (conference venue); Drug Discovery Research Department, Kobe Research Institute, HEALIOS K.K. (presenter's affiliation) |
| Quantitative Effects | Enhanced target antigen-specific cytotoxic activity, increased interferon-gamma production capacity, and potent antigen-specific cytotoxic activity against glioblastoma spheroids |
| Source | 30th Annual Meeting of the Japanese Association for Cancer Immunology (https://med-gakkai.jp/jaci2026/) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Glioblastoma is highly malignant, has a high recurrence rate, and is often resistant to standard treatment, creating a need for new therapeutic strategies. By simultaneously targeting EGFR and PD-L1, HEALIOS aims to develop a next-generation immune cell therapy suited to glioblastoma.